Treatment of gluten intolerance and related conditions
By using highly active Nepenthes protease to degrade gluten under low pH conditions, the problem of abnormal immune response to gluten in gluten-intolerant individuals is solved, and the relief of diseases such as celiac disease and the simplification of dietary management are achieved.
Patent Information
- Application Number
- CN201380070689.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2012-11-27
- Filing Date
- 2013-11-20
- Publication Date
- 2015-10-28
- Estimated Expiration
- 2033-11-20
AI Technical Summary
The digestion of gluten-containing wheat, barley, rye, etc. in individuals with gluten intolerance may trigger an abnormal autoimmune response, leading to celiac disease and other related conditions. Current treatments mainly rely on a lifelong strict gluten-free diet. However, it is difficult to avoid the presence of gluten and is not easy to implement.
It uses the enzyme Nepenthes protease, which has high protein and oligopeptide cleavage activity, especially under low pH conditions, and can effectively degrade gluten into non-toxic peptides, thereby regulating patients' gluten intolerance or related diseases. The enzyme can be administered as a food additive or alone to process foods containing gluten, reducing levels of toxic gluten proteins or peptides in the small intestine.
By degrading gluten into non-toxic peptides, reducing the autoimmune response caused by gluten, alleviating or inhibiting celiac disease, wheat allergy and other conditions, it provides an alternative treatment method for individuals with gluten intolerance, simplifies dietary management, and improves quality of life.